Advanced Accelerator Applications S.A.

Advanced Accelerator Applications SA develops, produces, and commercializes molecular nuclear, diagnostic, and therapeutic medicine products. It offers oxodotreotides; dotatate injections; edotreotide solutions; flurochol; and gluscan for oncology, cardiology, and neurology. It also provides LysaKare, a solution for reduction of kidney radiation exposure during peptide-receptor radionuclide therapy; DOPAVIEW, an aromatic amino acid that accumulates rapidly in target tissues; CARDIOGEN, closed system used to produce rubidium chloride for intravenous use; NEUROLITE, a radiopharmaceutical preparation of technetium bicisate injection; LUMARK, a radiopharmaceutical precursor; and LEUKOKIT, a medical device for the separation and labelling of autologous leukocytes. Additionally, it offers theragnostic platform, which is based on radiolabeling a targeting molecule for a receptor expressed on a tumor cell that helps in diagnosis, monitoring, and staging. The company was incorporated in 2002 and is based in Saint-Genis-Pouilly, France. Advanced Accelerator Applications SA operates as a subsidiary of Novartis AG.